Cargando…
1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
BACKGROUND: Beta-lactams have demonstrated superior outcomes over vancomycin in MSSA bacteremia. Despite this, studies of the anti-MRSA beta-lactam ceftaroline in MRSA bacteremia (MRSAB) are largely limited in size or focus on combination or salvage regimens. This study sought to further examine cef...
Autores principales: | Kamath, Meghan, Ma, Ariel, Johns, Scott T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644109/ http://dx.doi.org/10.1093/ofid/ofab466.1431 |
Ejemplares similares
-
474 Ceftaroline Salvage Therapy for MRSA Bacteremia Following Vancomycin Failure
por: Pettit, Natasha, et al.
Publicado: (2014) -
187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Kufel, Wesley D, et al.
Publicado: (2021) -
204. Clinical Outcomes with Ceftaroline Monotherapy versus Daptomycin-Ceftaroline Combination Therapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Andonie, Gabriela, et al.
Publicado: (2021) -
276. Comparison of Ceftaroline in Combination with Either Vancomycin or Daptomycin for the Treatment of Methicillin-resistant Staphylococcus aureus Bacteremia
por: Welch, Stephanie N, et al.
Publicado: (2020) -
1624. Real World Experience with Daptomycin (DAP) and Ceftaroline (CPT) Combination Therapy for Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia
por: Zidaru, Andrei, et al.
Publicado: (2020)